Dr. Sabine Hauk becomes Senior VP Corporate Development of Leukocare AG

The expert in formulation development is now taking the company forward at a strategic level

Dr Sabine Hauck Leukocare

Dr. Sabine Hauck, Senior Vice President Corporate Development bei Leukocare

“It is a great pleasure to take up the role as Senior VP Corporate Development. Since the time I joined Leukocare in 2017, my goal has always been to support the company´s development not only in terms of R&D but also on a strategic level. Thus, I am delighted to be in a position to make a decisive contribution to Leukocare´s corporate development.”

Dr. Sabine Hauck
Senior Vice President Corporate Development at Leukocare

Dr. Sabine Hauck headed the R&D department at Leukocare for the last four years. In her new role as Senior Vice President Corporate Development, Sabine is responsible for aligning strategic and technical goals to provide customers with tailor-made solutions in the field of drug product formulation development for biopharmaceuticals. Sabine has 20 years of drug product development expertise as well as several years of in vitro diagnostic and biosensor development. Before joining Leukocare, Sabine was heading Pharmaceutical Development, Quality Assurance and Regulatory Affairs departments at Medigene AG, Martinsried, Germany, Acino International AG, Zurich, Switzerland and IDEA Pharma AG, Basel, Switzerland and Munich, Germany. She holds a Dr. rer. nat. from University of Regensburg, Germany.

Dr. Sabine Hauck, Senior Vice President Corporate Development at Leukocare, said, “It is a great pleasure to take up the role as Senior VP Corporate Development. Since the time I joined Leukocare in 2017, my goal has always been to support the company´s development not only in terms of R&D but also on a strategic level. Thus, I am delighted to be in a position to make a decisive contribution to Leukocare´s corporate development”.

“I am extremely happy to have Sabine taking over as Senior VP Corporate Development. In her new position, she will play a decisive role in further driving Leukocare’s strategy to meet our customers’ needs at the best,” explains Michael Scholl, CEO Leukocare AG